Alvotech Collaborates with Dr. Reddy’s to Commercialize AVT03 (Biosimilar, Prolia & Xgeva)
Shots:
- Alvotech & Dr. Reddy’s have signed a license & supply agreement to commercialize AVT03 under which Alvotech will handle the development & manufacturing activities. Dr. Reddy will get regulatory & commercial rights exclusively in US and semi-exclusively in the EU & UK
- Alvotech will receive an upfront, regulatory & commercial milestones as well as sales-based payments
- Additionally, in Jan 2024, the company reported top-line data of a PK study assessing safety, PK & tolerability of AVT03 vs Prolia in healthy adults. A confirmatory efficacy & safety study in patients & a PK study of AVT03 vs Xgeva in healthy adults are ongoing
Ref: Alvotech | Image: Alvotech
Related News:- Alvotech Reports Data from the Trial of AVT03 (Biosimilar, Prolia and Xgeva) for Skeletal Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
